CinCor Pharma Net Income

CinCor Pharma posts a net income of $-93M as of September 2022. That compares with $-27M in the prior-year period — down 247.7% year over year. That is below the sector sector average of $90M. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, CinCor Pharma's net income was $-27M. The latest reading is $-93M — a 247.7% year-over-year decrease (period ending September 2022). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a net income near $90M is typical. CinCor Pharma's $-93M is lower that level. That is roughly 203.4% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Net Income is one piece of CinCor Pharma's financial statement story. At $-93M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CINC's net income usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $90M), and (3) consistency with growth and profitability. This page covers the first two; CinCor Pharma's other metric pages and overview cover the third.